Heartflow Plaque Analysis Now Supported by Scientific Statements From American College of Cardiology and American Heart Association for Personalized Management of Patients with Suspected CAD

Impact · against what's priced in

The scientific statements from the ACC and AHA provide critical clinical legitimacy and a standardized pathway for Heartflow's AI plaque analysis, potentially accelerating adoption. By moving the technology from 'emerging' to a 'defined clinical consideration,' the company expands its addressable market for nonobstructive CAD management.

HTFL+0.70

No priced-in read yet